BIOMAT Database Logo BIOMAT Database Logo

Binding characteristics of naftopidil and alpha 1-adrenoceptor antagonists to prostatic alpha-adrenoceptors in benign prostatic hypertrophy. 1992

S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Japan.

Binding properties of naftopidil and alpha 1-adrenoceptor antagonists to alpha-adrenoceptors in prostates from benign prostatic hypertrophy (BPH) were characterized by radioreceptor assays using [3H]prazosin and [3H]rauwolscine. Specific binding of [3H]prazosin and [3H]rauwolscine in human prostatic membranes was saturable and of high affinity, and it showed a pharmacological specificity which characterized alpha 1 and alpha 2-adrenoceptors, respectively. Naftopidil and several alpha 1 antagonists competed for prostatic [3H]prazosin binding in order: R-(-)-YM-12617 greater than prazosin greater than bunazosin greater than terazosin greater than naftopidil greater than urapidil, and the inhibitory effect (Ki = 11.6 nM) of naftopidil was 10 to 45 times less potent than quinazoline derivatives such as prazosin, bunazosin and terazosin. The potencies of these antagonists in competing for [3H]prazosin binding sites in human prostates correlated well with their pharmacological potencies (pA2). Scatchard analysis indicated that the decrease of prostatic [3H]prazosin binding by naftopidil was due to a marked increase in the Kd value without a change in the Bmax value. The inhibition of prostatic [3H]prazosin binding by naftopidil was reversible. Naftopidil also inhibited prostatic [3H]rauwolscine binding (Ki = 70.0 nM). Thus, it is suggested that naftopidil antagonizes alpha 1-adrenoceptors in human prostates in a competitive and reversible manner.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011942 Receptors, Adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation. Adrenergic alpha-Receptor,Adrenergic alpha-Receptors,Receptors, alpha-Adrenergic,alpha-Adrenergic Receptor,alpha-Adrenergic Receptors,Receptor, Adrenergic, alpha,Adrenergic alpha Receptor,Adrenergic alpha Receptors,Receptor, alpha-Adrenergic,Receptors, alpha Adrenergic,alpha Adrenergic Receptor,alpha Adrenergic Receptors,alpha-Receptor, Adrenergic,alpha-Receptors, Adrenergic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic

Related Publications

S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Clinical experience with alpha-adrenoceptor antagonists in benign prostatic hypertrophy.
October 1986, Federation proceedings,
S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists.
April 2002, World journal of urology,
S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
High-affinity specific [3H]tamsulosin binding to alpha 1-adrenoceptors in human prostates with benign prostatic hypertrophy.
January 1994, Urological research,
S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
October 2009, The Prostate,
S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy.
July 1987, The Journal of pharmacology and experimental therapeutics,
S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.
June 1996, British journal of pharmacology,
S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Increased bladder apoptosis with alpha-1 adrenoceptor antagonists in benign prostatic hyperplasia.
April 2003, The Journal of urology,
S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Increased bladder apoptosis with alpha-1 adrenoceptor antagonists in benign prostatic hyperplasia.
January 2002, Scandinavian journal of urology and nephrology,
S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
January 1996, European urology,
S Yamada, and M Suzuki, and Y Kato, and R Kimura, and R Mori, and K Matsumoto, and M Maruyama, and K Kawabe
Alpha 1-adrenoceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists.
January 1994, Life sciences,
Copied contents to your clipboard!